EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma

Nguyen H Tran iD, Mathias E Palmer iD, Angela Ulrich, Shaylene A McCue, Amit Mahipal iD, Wen Wee Ma iD, Hani M Babiker iD, Umair Majeed, Thorvardur R Halfdanarson iD, Robert R McWilliams iD, Zhaohui Jin iD, Ryan Carr iD und 19 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag343 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2026. Verfasst von Nguyen H Tran und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Optimal treatment following first-line immunotherapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study evaluated futibatinib, a pan-FGFR inhibitor, combined with pembrolizumab in previously treated patients with FGF19-expressing HCC.

Methods

Eligible patients were ≥18 years old with advanced HCC, prior systemic therapy, Child-Pugh A-B7 liver function, ECOG 0-2, and FGF19 overexpression. Patients received futibatinib 20 mg orally daily plus pembrolizumab 200 mg intravenously every 3 weeks. The primary endpoint was progression-free survival at 6 months (PFS6). Secondary endpoints included overall survival (OS), objective response rate (ORR), quality of life, and safety.

Results

Between August 2021 and March 2024, 14 patients enrolled and 13 were evaluable. Median age was 72 years (range, 60-87), 53.8% were male, 92.3% had Child-Pugh A liver function, and all had received prior immunotherapy. Median progression-free survival was 15 weeks (95% CI, 9.0-NE), with a PFS6 rate of 23.1% (95% CI, 8.6-62.3%). ORR was 0% (95% CI, 0-24.7%), while stable disease was observed in 53.9% of patients. Median OS was 55.7 weeks (95% CI, 47.3-NE). Grade ≥3 adverse events occurred in 69.2% of patients, and grade ≥4 adverse events in 15.4%. One grade 5 event (acute-on-chronic kidney injury) was deemed unrelated to treatment. Common adverse events included hyperphosphatemia, fatigue, diarrhea, elevated transaminases, dry eye, nail changes, rash, and oral mucositis.

Conclusions

Futibatinib plus pembrolizumab demonstrated an acceptable safety profile but did not meet efficacy thresholds supporting further study in FGF19-expressing HCC. Effective post-immunotherapy treatment strategies remain an unmet need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, HepatocellularLiver NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFibroblast Growth FactorsHumansMaleAgedFemaleMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

FGFR inhibitoradvanced hepatocellular carcinomafutibatinibimmunotherapypembrolizumab

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabFibroblast Growth Factors

Autor:innen und Institutionen

  • Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, United States.
  • Department of Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH 44106, United States.
  • Department of Hematology/Oncology, Cleveland Clinic Cancer Center, Cleveland, OH 44195, United States.
  • Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32224, United States.
  • OSF HealthCare Cancer Institute, Peoria, IL 61603, United States.

ORCID-Profile: Nguyen H Tran, Mathias E Palmer, Amit Mahipal, Wen Wee Ma, Hani M Babiker, Thorvardur R Halfdanarson, Robert R McWilliams, Zhaohui Jin, Ryan Carr, Lionel Aurelien Kankeu Fonkoua, Leslie Washburn, Caitlin Conboy, Rondell P Graham, Patrick Starlinger, Krishan R Jethwa, Ajit H Goenka, Sudhakar K Venkatesh, Mohamad B Sonbol, Tanios Bekaii-Saab, Lewis R Roberts, Julie K Heimbach, Fang-Shu Ou

Förderung

  • NCI NIH HHS

Zitieren

APA

Tran, N. H., Palmer, M. E., Ulrich, A., McCue, S. A., Mahipal, A., Ma, W. W., Babiker, H. M., Majeed, U., Halfdanarson, T. R., McWilliams, R. R., Jin, Z., Carr, R., Kankeu Fonkoua, L. A., Washburn, L., Conboy, C., Graham, R. P., Torbenson, M., Starlinger, P., Jethwa, K. R., …, & Ou, F. S. (2026). Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyag343

Vancouver

Tran NH, Palmer ME, Ulrich A, McCue SA, Mahipal A, Ma WW, et al. Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma. The Oncologist. 2026. doi:10.1093/oncolo/oyag343

BibTeX
@article{Tran2026,
  author = {Tran, Nguyen H and Palmer, Mathias E and Ulrich, Angela and McCue, Shaylene A and Mahipal, Amit and Ma, Wen Wee and Babiker, Hani M and Majeed, Umair and Halfdanarson, Thorvardur R and McWilliams, Robert R and Jin, Zhaohui and Carr, Ryan and Kankeu Fonkoua, Lionel Aurelien and Washburn, Leslie and Conboy, Caitlin and Graham, Rondell P and Torbenson, Michael and Starlinger, Patrick and Jethwa, Krishan R and Hallemeier, Christopher and Revzin, Alexander and Thompson, Scott M and Goenka, Ajit H and Venkatesh, Sudhakar K and Sonbol, Mohamad B and Borad, Mitesh J and Bekaii-Saab, Tanios and Gores, Gregory J and Roberts, Lewis R and Heimbach, Julie K and Ou, Fang-Shu},
  title = {Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag343}
}
Kostenlos starten →